Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company
Acquiring Company
Bristol Myers Squibb
Acquired Company
Turning Point Therapeutics
PrincetonManufacturingBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementHealth CareScience And EngineeringDescription
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Boards of Directors and is anticipated to close during the third quarter of 2022.
Quick answer
Bristol Myers Squibb is acquiring Turning Point Therapeutics, announced June 3, 2022. Bristol Myers Squibb is based in Princeton, New Jersey, United States.
- How much did Bristol Myers Squibb pay for Turning Point Therapeutics?
- The deal value was not disclosed.
- What does Bristol Myers Squibb do?
- Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
- Where are Bristol Myers Squibb and Turning Point Therapeutics based?
- Bristol Myers Squibb is based in Princeton, New Jersey, United States.
- Who are the decision-makers at Bristol Myers Squibb?
- Fundz holds 2 contacts at Bristol Myers Squibb. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Professional Services and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Halozyme Completes Antares Pharma Acquisition (May 24, 2022)
- U.S. Alliance Pharma Acquires U.K.-Based Lgc’S Drug Development Solutions (Dds) Business (July 13, 2022)
- Pfizer To Acquire Biohaven Pharmaceuticals (May 10, 2022)
- Hikma Completes Acquisition Of Custopharm (April 21, 2022)
- Regeneron Completes Acquisition Of Checkmate Pharmaceuticals (May 31, 2022)
- Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals Inc. And Reports First Quarter 2022 Financial Results (May 16, 2022)
Who to call at Bristol Myers Squibb, and when
When Bristol Myers Squibb changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Bristol Myers Squibb raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bristol Myers Squibb, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bristol Myers Squibb. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bristol Myers Squibb makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Turning Point Therapeutics?
Turning Point Therapeutics was acquired by Bristol Myers Squibb, based in Princeton. The deal was reported on June 3, 2022. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb is publicly traded (BMY) and operates in Manufacturing.
When did Bristol Myers Squibb acquire Turning Point Therapeutics?
Bristol Myers Squibb's acquisition of Turning Point Therapeutics was reported on June 3, 2022. Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Turning Point Therapeutics do?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. It is privately held, operating in Health Care.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.